Greater Confidence in the Rule Out of Urothelial Cancer

Cxbladder is a suite of genomic urine tests optimised for the rule-out and surveillance of urothelial cancer in patients presenting with haematuria and those being monitored for recurrent disease. The tests help you prioritise your time and clinical resources, optimise your practice workﬂow, and improve the overall patient experience.

Enables reliable risk stratification. Safely de-intensifies clinical workup in low risk patients, while prioritising higher risk patients for immediate care.
Helps resolve atypical cytology and equivocal cystoscopy.
Offers a non-invasive surveillance alternative that can reduce the burden of repeated cystoscopy in those with a low risk of recurrence, improving comfort and compliance.

Cxbladder works at a molecular level, analysing five biomarker genes to help rule out urothelial cancer.

Objective and reliable: Exceptional performance and clinically actionable results.
Clinically proven: Proven performance in over 20 peer-reviewed publications for primary detection and surveillance. Cxbladder has been used by over 4,400 US urologists in more than 100,000 patients. In New Zealand, the test is now available to 75% of the population through public healthcare.
Easy-to-use: Cxbladder’s unique urine sample collection system is non-invasive and easy for both clinical teams and patients to use.
Quick: Upon receiving a urine sample, our certified laboratory will provide actionable results in 5 business days.

A Suite of Tests Optimised for Hematuria Evaluation and Surveillance

Haematuria Evaluation

Cxbladder Triage

Cxbladder Triage is a diagnostic test optimised for primary care. With high NPV, the test helps to de-intensify clinical work-up in haematuria patients with a low probability of urothelial cancer, reducing the need for referral and invasive procedures, while prioritising those who require further investigation.

Analyses gene expression alongside information on known UC risk factors like age, gender and smoking history to help rule out hematuria patients with a low risk of disease, while prioritising those who require further investigation.
Supports a new model for clinical practice and resource utilisation. This deployment model provides care to the greatest number of patients and offers clinically actionable information at the earliest point in the patient care pathway.

Featured study: STRATA

Our STRATA study, demonstrating Cxbladder Triage can safely and more effectively risk-stratify low risk haematuria patients compared to American Urological Association (AUA) guidelines, has now been published in the Journal of Urology. STRATA is the first ever randomised controlled trial of a urine biomarker for haematuria evaluation.

Cxbladder Detect

Cxbladder Detect is designed to improve practice workflow and efficiency, while giving patients the best experience possible. The test is optimised for the rule out of urothelial cancer in patients presenting with haematuria.

Enables reliable risk stratification. Safely de-intensifies clinical workup in low-risk patients, while prioritising higher risk patients for immediate care.
Spares low risk patients the discomfort, anxiety and risks of an invasive procedure.
Helps resolve diagnostic dilemmas like atypical cytology and equivocal cystoscopy.

Surveillance

Cxbladder Monitor

Cxbladder Monitor is a non-invasive surveillance alternative that can reduce the burden of repeated cystoscopy in non-muscle invasive bladder cancer patients with a low risk of recurrence, improving patient comfort and compliance.

In suitable cases post, can alternate with cystoscopy to de-intensify surveillance.
May be used to replace cystoscopy in patients with no recurrence long term after shared decision making with the patient.